89 related articles for article (PubMed ID: 7683064)
21. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
[TBL] [Abstract][Full Text] [Related]
22. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
23. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
24. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
25. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts].
Hagiwara S; Yuo A; Nagai M; Takezako N; Soda Y; Miwa A; Togawa A; Takaku F
Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658
[TBL] [Abstract][Full Text] [Related]
26. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
27. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
[TBL] [Abstract][Full Text] [Related]
28. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
29. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome.
Beran M
Int J Hematol; 2000 Aug; 72(2):139-50. PubMed ID: 11039661
[TBL] [Abstract][Full Text] [Related]
30. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
31. [Colony stimulating factor].
Takaku F
Gan To Kagaku Ryoho; 1989 Nov; 16(11):3550-3. PubMed ID: 2817907
[TBL] [Abstract][Full Text] [Related]
32. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
33. GM-CSF, ARA-C, VP-16 and idarubicin (GM-IVA), a short, and effective induction treatment for de novo AML, suitable for the elderly.
Pierri I; Clavio M; Beltrami G; Cavaliere M; Lanza L; Miglino M; Canepa L; Pietrasanta D; Ballerini F; Quintino S; Gatto S; Celesti L; Carrara P; Varese P; Gobbi M
J Exp Clin Cancer Res; 1999 Mar; 18(1):55-60. PubMed ID: 10374678
[TBL] [Abstract][Full Text] [Related]
34. Low-dose Ara-C plus granulocyte/macrophage colony-stimulating factor for the treatment of myelodysplastic syndromes. EORTC Leukemia Group.
Gerhartz HH; Visani G; Delmer A; Zwierzina H; Ribeiro M; Jacobs A; Marcus R; Baumelou M; Fière D; Labar B
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():36-7. PubMed ID: 2697397
[No Abstract] [Full Text] [Related]
35. Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia.
Zhang WG; Wang FX; Chen YX; Cao XM; He AL; Liu J; Ma XR; Zhao WH; Liu SH; Wang JL
Am J Hematol; 2008 Mar; 83(3):185-8. PubMed ID: 17899614
[TBL] [Abstract][Full Text] [Related]
36. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
37. The treatment of myelodysplastic syndromes.
Spriggs DR; Stone RM; Kufe DW
Clin Haematol; 1986 Nov; 15(4):1081-107. PubMed ID: 3552348
[TBL] [Abstract][Full Text] [Related]
38. [Clinical study of GM-CSF in patients with aplastic anemia and myelodysplastic syndrome. (CSF39-300 Study Group)].
Kitamura K; Asano S; Mizoguchi H; Takaku F
Rinsho Ketsueki; 1993 Dec; 34(12):1540-9. PubMed ID: 8295327
[TBL] [Abstract][Full Text] [Related]
39. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
40. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]